Topical tacrolimus in the management of lichen sclerosus [4]

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 113, Issue 12, 2006, Pages 1482-

  Edey, K ^a   Bisson, D ^a   Kennedy, C ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; PIMECROLIMUS; TSUKUBAENOLIDE;

CLINICAL TRIAL; EUROPE; FOOD AND DRUG ADMINISTRATION; HOSPITAL CARE; HUMAN; LETTER; LICHEN SCLEROSUS ET ATROPHICUS; LYMPHOMA; POPULATION RESEARCH; PRIORITY JOURNAL; SKIN CARCINOMA; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LICHEN SCLEROSUS ET ATROPHICUS; TACROLIMUS; VULVAR DISEASES;

EID: 33750956744     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2006.01103.x     Document Type: Letter

References (7)

1. Luesley D, Downey G. Topical tacrolimus in the management of Lichen Sclerosus. BJOG 2006;113:832-4.
2. US Food and Drug administration. FDA approves updated labelling with boxed warning and medication guide for 2 eczema drugs, Elidel and Protopic [www.fda.gov/bbs/topics/news/2006/NEW01299.html]. Accessed 8 August 2006.
3. Topical tacrolimus and pimecrolimus: reports of malignancies. Curr Probl Pharmacovigilance 2006;31:1-2.
4. Smith YR, Haefner HK. Vulval lichen sclerosus: pathophysiology and treatment. Am J Clin Dermatol 2004;5:105-25.
5. Kawashima M, Nakagawa H, Ohtsuki M, Tamaki K, Ishibashi Y. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. Lancet 1996;348:1240-1.
6. Quereshi A, Fischer M. Topical calcineurin inhibitors for atopic dermatitis. Arch Dermatol 2006;142:633-7.
7. Ormerod A. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol 2005;153:701-5.